Literature DB >> 1052780

Structure activity studies on somatostatin.

D Sarantakis, W A McKinley, I Jaunakais, D Clark, N H Grant.   

Abstract

Seven synthetic analogues of somatostatin helped clarify structural requirements for suppression of growth hormone secretion in rats. Size of the ring is not critical; deletions of serine-13, lysine-4 or asparagine-5 result in peptides which retain an appreciable fraction of the activity. The analogue des-Ala1, Gly2, Asn5-somatostatin lowers plasma growth hormone and insulin levels without affecting plasma glucagon levels significantly.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1052780     DOI: 10.1111/j.1365-2265.1976.tb03835.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Structure-activity relationships of somatostatin analogs in the rabbit ileum and the rat colon.

Authors:  L E Rosenthal; D J Yamashiro; J Rivier; W Vale; M Brown; K Dharmsathaphorn
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

2.  Structure-activity relationships of eighteen somatostatin analogues on gastric secretion.

Authors:  M P Brown; D H Coy; A Gomez-Pan; B H Hirst; M Hunter; C Meyers; J D Reed; A V Schally; B Shaw
Journal:  J Physiol       Date:  1978-04       Impact factor: 5.182

3.  Effect of the somatostatin analog D-Trp8,D-Cys14 on glucose insulin, pancreatic glucagon and growth hormone plasma levels in acromegalics and mild diabetics.

Authors:  M Trovati; F Massara; F Camanni; G M Molinatti; R Lorenzati; G F Pagano
Journal:  J Endocrinol Invest       Date:  1980 Apr-Jun       Impact factor: 4.256

4.  Effect of a somatostatin analog on insulin requirement and hormone levels in 6 insulin-dependent juvenile-onset diabetics subjected to artificial pancreas.

Authors:  G Lenti; M Trovati; R Lorenzati; F Vitelli; V Tagliaferro; A Marocco; G Pagano
Journal:  Acta Diabetol Lat       Date:  1980 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.